DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
10,300
Employees10,300
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
10,300
Employees10,300

DXCM Key Statistics

Market cap
28.41B
Market cap28.41B
Price-Earnings ratio
40.55
Price-Earnings ratio40.55
Dividend yield
Dividend yield
Average volume
7.32M
Average volume7.32M
High today
$74.04
High today$74.04
Low today
$71.70
Low today$71.70
Open price
$72.95
Open price$72.95
Volume
5.25M
Volume5.25M
52 Week high
$93.25
52 Week high$93.25
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

With a market cap of 28.41B, DexCom(DXCM) trades at $72.23. The stock has a price-to-earnings ratio of 40.55.

As of 2026-01-26, DexCom(DXCM) stock has fluctuated between $71.70 and $74.04. The current price stands at $72.23, placing the stock +0.7% above today's low and -2.4% off the high.

The DexCom(DXCM)'s current trading volume is 5.25M, compared to an average daily volume of 7.32M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.

In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.

DXCM News

Simply Wall St 2d
How Investors Are Reacting To DexCom Revenue Guidance After G7 Recall and CGM Expansion Plans

In January 2026, DexCom, Inc. issued preliminary unaudited results and guidance, projecting fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2...

How Investors Are Reacting To DexCom Revenue Guidance After G7 Recall and CGM Expansion Plans
Simply Wall St 5d
Assessing DexCom Valuation After Updated Double Digit Growth Guidance Through 2026

DexCom (DXCM) has drawn investor attention after issuing preliminary revenue guidance that points to double digit growth targets for late 2025 and 2026, support...

Assessing DexCom Valuation After Updated Double Digit Growth Guidance Through 2026

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.